Castle Biosciences (CSTL) Accumulated Expenses (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Accumulated Expenses data on file, last reported at $19.1 million in Q1 2026.

• Quarterly Accumulated Expenses rose 7.02% year-over-year to $19.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.1 million (up 7.02% YoY) and the FY2025 annual result came in at $38.3 million, up 17.61% from the prior year.
• Accumulated Expenses retreated to $19.1 million in Q1 2026 per CSTL's latest filing, from $38.3 million in the prior quarter.
• The five-year high for Accumulated Expenses was $38.3 million in Q4 2025, with the low at $8.6 million in Q1 2022.
• Average Accumulated Expenses over 5 years is $22.2 million, with a median of $21.2 million recorded in 2024.
• Year-over-year, Accumulated Expenses jumped 73.0% in 2022 and rose 7.02% in 2026.
• Castle Biosciences' Accumulated Expenses stood at $24.4 million in 2022, then grew by 18.83% to $28.9 million in 2023, then grew by 12.47% to $32.6 million in 2024, then grew by 17.61% to $38.3 million in 2025, then sank by 50.08% to $19.1 million in 2026.
• Business Quant data shows CSTL's Accumulated Expenses at $19.1 million in Q1 2026, $38.3 million in Q4 2025, and $31.8 million in Q3 2025.